UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive topline results from the RAISE (NCT04115293) triali evaluating its...
Source: prnewswire.com